187 results about "Keratinocyte" patented technology

Provided are a whitening and freckle-removing composition, a gel, a preparation method therefor, and a use thereof, relating to the technical field of skin-care products. The whitening and freckle-removing composition comprises tranexamic acid, nicotinamide, 4-butylresorcinol, licorice extract, 3-o-ethyl ascorbic acid, and glutathione. For the whitening composition, by inhibiting the activity of tyrosinase, blocking the transfer of melanin from melanocytes to keratinocytes, and inhibiting the formation and accumulation of melanin by means of multiple mechanisms including oxidation resistance, and by means of the synergistic action of all components, cosmetic benefits of whitening and freckle-removing are achieved. The whitening and freckle-removing gel has a simple preparation method, has a mild and non-sensitizing formula, is safe and non-irritating, and is suitable for large-scale production and application.

The invention relates to an application of D-camphor and cymenin in preparation of an anti-inflammatory soothing preparation for sensitive skin. The invention discloses an application of D-camphor and cymenin as only two effective components in preparation of an anti-inflammatory soothing preparation for sensitive skin. The invention further discloses an anti-inflammatory soothing preparation for sensitive skin, only two effective components of the anti-inflammatory soothing preparation for sensitive skin are D-camphor and cystin, and the anti-inflammatory soothing preparation for sensitive skin can reduce the reaction of IL-6, IL-8 and NO related microinflammation in a keratinocyte inflammation model. The invention has the following beneficial effects: 1, in a high proportion window (5-10: 1) of D-camphor and polycymenin, the inhibition of the compound system of D-camphor and polycymenin on IL-6, IL-8 and NO is superior to that of any monomer; 2, stable dispersion and good use experience can be realized through the micro-emulsion type emulsifying essence or the face cream carrier, and meanwhile, the face cream still has feasibility under the conditions of no essence and no conventional preservative.

The invention relates to the field of cosmetics, in particular to dendrobium devonianum stem extract as well as a preparation method and application thereof. The invention provides a dendrobium devonianum stem extract. The mass ratio of glucose to mannose in the dendrobium devonianum stem extract is 3: 7. The invention provides the dendrobium devonianum stem extract with tightening and moisturizing functions, and the extract can effectively inhibit ROS secreted by UVB-induced in-vitro keratinocytes at a lower concentration, and has a certain tightening effect; the AQP3 level in keratinocytes is improved, the AQP3 gene expression is up-regulated, and a certain moisturizing effect is achieved; the dendrobium devonianum stem extract is used for a formula human body efficacy test, and it is proved that 0.1% of the dendrobium devonianum stem extract has certain tightening and moisturizing effects.

The invention discloses a hydrogel dressing for treating atopic dermatitis and a preparation method and application thereof, and belongs to the technical field of skin medical materials. The dressing is prepared by taking a glycerol / water / ethanol ternary mixed solvent as a dissolving system, dissolving polyvinyl alcohol, tannic acid and aluminum trichloride to construct a polymer skeleton matrix, and then adding traditional Chinese medicine active ingredients. The preparation does not need complex temperature control curing, the ternary solvent can realize uniform dissolution and stable dispersion of the active ingredients, the effective ingredients are prevented from being damaged by high temperature, the encapsulation efficiency of the traditional Chinese medicine extract is more than 90%, and the medicine can be slowly released for 72 hours. The dressing has a multi-target anti-inflammatory effect, can reduce the level of TNF-alpha at a skin lesion and promote proliferation of keratinocytes, is excellent in tensile and torsional stability, and can be attached to the skin for a long time in a dynamic environment. The preparation method is simple in process, controllable in raw material cost, high in production efficiency, suitable for large-scale production, good in dressing biocompatibility, high in safety, suitable for treatment of atopic dermatitis of different severity degrees and large in clinical transformation potential.

The present invention relates to a method for producing a skin tissue model, comprising: (a) isolating and culturing fibroblasts and keratinocytes from skin tissue; (b) preparing a bioink composition for a dermal layer and a bioink composition for an epidermal layer, the bioink composition containing the isolated cells; and (c) producing a skin tissue model using the bioink composition for a dermal layer and the bioink composition for an epidermal layer.

To provide a method for simply and efficiently evaluating the inducibility of a foreign matter response reaction in the skin of a test sample without using an animal, and to provide a substance having the inhibitory properties of the foreign matter response reaction in the skin and a method for searching the same.SOLUTION: The method includes a step of bringing keratinocytes transformed with a vector having an enhancer sequence containing a foreign body-responsive sequence and a sequence encoding a reporter protein downstream of the enhancer sequence into contact with a solution containing a test sample, a step of measuring the expression level of the reporter protein in the keratinocytes, and a step of evaluating the inducibility of a foreign body response reaction of the test sample in the skin based on the expression level of the reporter protein. The problem is solved by providing an agent for suppressing foreign matter response reaction in the skin containing fregula 1 found by the search method.SELECTED DRAWING: Figure 3

The invention discloses TCN1 (Trancobalamin 1, cobalamin 1) and application of an inhibitor of the TCN1 in preparation of products for diagnosing and treating diseases of an autoimmune system. According to the invention, expression in psoriasis tissues is up-regulated and promoter DNA methylation is down-regulated into genes to screen TCN1 genes, an over-expression TCN1 HaCaT cell line is constructed, and it is verified that the over-expression TCN1 HaCaT cell line participates in keratinocyte proliferation and IL-17 activation as an autoantigen, can be used as a diagnostic marker and a therapeutic target of autoimmune skin diseases such as psoriasis and the like, and has broad application prospects. And a new direction is provided for mechanism research and treatment of autoimmune skin diseases such as psoriasis.

The invention provides a novel medicine for treating psoriasis by recovering keratinocyte Pp6 and application of the novel medicine. The novel medicine has the structural formula shown in the formula (I), has the remarkable effects of inhibiting epidermal hyperplasia, reducing the infiltration number of dermal inflammatory cells and the like on a psoriasis focus area, and has the very excellent relieving or treating effect on psoriasis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a marine small molecule peptide and an active variant thereof in preparation of a medicine for treating skin diseases, the marine small molecule peptide and the active variant thereof can effectively inhibit keratinocyte pan apoptosis induced by TNF-alpha and IFN-gamma, the formation of a PANoptosome complex is blocked through a multi-target synergistic effect, and the effect of treating the skin diseases is achieved. The oxidative stress is reduced, and mitochondria is stabilized, so that a skin inflammatory cell death network is inhibited from the source. The variant has the same high sequence as the peptide, retains the activity of inhibiting cell pan-apoptosis, and has enhanced stability, skin permeability, in vivo half-life or efficacy. Based on the action mechanism, the peptide and the variant thereof can be used for preparing medicines for preventing and treating intractable skin diseases such as epidermis necrolysis, psoriasis, atopic dermatitis, skin lupus erythematosus and lichen planus. The invention also provides a composition containing the peptide or the variant thereof, and dosage forms comprise an external preparation and an injection.

The application discloses application of 12-ketolithocholic acid in preparation of a medicine for preventing or treating atopic dermatitis, and the 12-ketolithocholic acid can inhibit NUAK2 kinase activity expression and activity, and then negatively regulates a downstream TNF inflammatory signal path, significantly down-regulates IL-1beta, IL-8 and various proinflammatory factor secretion, and inhibits keratinocyte excessive inflammatory activation. The 12-ketolithocholic acid and ginsenoside F2 are compounded and used in combination to produce synergistic effect, and the anti-inflammatory effect is further enhanced; the active substance has low cytotoxicity and good safety, can be prepared into an external ointment or an oral preparation, and has a wide application prospect in the field of atopic dermatitis prevention and treatment.

The invention discloses a whitening composition as well as a preparation method and application thereof. The whitening composition is prepared from the following components: a tea leaf extract, a lavender flower extract and water, wherein the tea leaf extract, the lavender flower extract and the water are added into the whitening composition. The whitening composition can interact and synergistically improve the autophagy ability of cells, synergistically improve the phagocytosis of melanin in keratinocytes and the removal ability of skin metabolic wastes, can synergistically inhibit the generation of melanin and synergistically improve the expression of miR-137 genes in melanocytes, has a relatively high development prospect of cosmetics with whitening effects, and has a wide application prospect. Moreover, the composition is mild in property, easy to absorb and non-irritant, and can be widely applied to skin care cosmetics.

The invention discloses a hederacoside C deglycosylation derivative and a preparation method and application thereof.The hederacoside C deglycosylation derivative is prepared from hederacoside C through specific glycosidase hydrolysis, different products can be flexibly regulated and enriched on the basis of selectivity of different glycosidase to glucosidic bonds and glycosyl sites, the preparation method is simple, reaction conditions are mild, and the hederacoside C deglycosylation derivative is suitable for industrial production. The method is suitable for large-scale mass production. The hederacoside C deglycosyl derivative does not show obvious cytotoxicity to human immortalized keratinocytes, has the effect of promoting cell proliferation and the activity of promoting cell migration, and can obviously inhibit LPS (lipopolysaccharide)-induced cell apoptosis. Besides, the partial hederacoside C deglycosyl derivatives can reduce inflammatory factor level rise caused by wounds, remarkably promote wound healing and reduce formation of wound scars, and have good application prospects in preparation of drugs or skin care products for promoting wound repair.

The invention discloses a pharmaceutical composition with skin repairing, anti-inflammatory and anti-aging effects as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition mainly comprises a stem cell exosome and a fusion polypeptide-single domain antibody conjugate, and can also comprise proline and pharmaceutically acceptable auxiliary materials. The amino acid sequence of the fusion polypeptide is as shown in SEQ ID NO.1, and the fusion polypeptide can specifically target skin cells; the single-domain antibody is an anti-IL-6 single-domain antibody, the amino acid sequence of the single-domain antibody is shown as SEQ ID NO.2, and the single-domain antibody can efficiently inhibit inflammatory factors. Experiments show that through the synergistic effect of all the components, the composition remarkably promotes proliferation of skin fibroblasts and keratinocytes, inhibits secretion of inflammatory factors such as IL-6 and TNF-alpha, promotes synthesis of collagen, effectively improves skin aging and inflammation states and has wide application prospects in the fields of skin repair, inflammation resistance and senescence resistance.

The application belongs to the technical field of medicines, and specifically provides application of Phanginin A in preparation of medicines for preventing and / or treating skin diseases. The skin diseases include atopic dermatitis and skin epidermal barrier damage. The application finds that Phanginin A can reduce atopic dermatitis lesion scores, improve atopic dermatitis skin pathological thickening and inflammatory cell infiltration, reduce spleen inflammatory response, inhibit volume increase, promote thymus function recovery, down-regulate expression of atopic dermatitis related inflammatory factors IL-6 and TNF-alpha, and can be used for preventing and / or treating atopic dermatitis. In addition, the application also finds that Phanginin A can promote keratinocyte scratch healing, and can be used for repairing skin epidermal barrier damage.

The invention relates to the technical field of cosmetics, in particular to a compound active peptide with functions of resisting aging and whitening skin and application of the compound active peptide. Comprising acetyl hexapeptide-1, nonapeptide-1, acetyl tetrapeptide-11, hexapeptide-9 and palmitoyl hexapeptide-12. The compound peptide disclosed by the invention can play a synergistic anti-aging and whitening role on an epidermal layer and a corium layer, and has multiple advantages; the compound peptide acts on epidermal layer keratinocytes, dermal layer fibroblasts and B16F10 cells, and can be used for detecting the senescence of the cells by influencing the expression quantity of cell senescence marker genes, influencing the cell cycle, influencing the expression quantity of extracellular matrix related proteins, influencing melanin synthesis and influencing the secretion quantity of acetylcholine in the cells. Multiple skin anti-aging and whitening effects synergistically exerted on the epidermal layer and the corium layer are achieved.

The invention provides a composition with an effect of relieving keratosis pilaris and a preparation method of the composition, and relates to the technical field of cosmetics. The allantoin in the raw materials can directly act on keratin of skin, increase and promote the hydration capacity of cuticle, soften skin cuticle protein and remove keratinocytes, and acts together with the hydroxyethyl piperazine ethanesulfonic acid to promote falling of aged cuticle and promote cell proliferation and tissue growth, so that the skin care effect is improved. The updating speed of keratinocytes and a small part of upper epidermis cells is accelerated, so that the aged skin is regenerated, and the keratosis pilaris is improved. The composition provided by the invention is mild in components and good in effect.

The invention discloses a cell composition for promoting hair regeneration and application thereof, and belongs to the field of biological medicine, the active component of the cell composition comprises a mixture of hair papilla cells, keratinocytes and stem cell growth factors; wherein the number ratio of the hair papilla cells to the keratinocytes is (1-3): (1-3), and the stem cell growth factor mixture comprises bFGF, KGF, HGF, VEGF, TGF-beta1 and PDGF. The cell preparation disclosed by the invention can be used for improving the hair growth effectiveness and solving different types of alopecia symptoms except for androgen alopecia, has a remarkable treatment effect on androgen alopecia, and has a remarkable effect on treating various alopecia symptoms. The traditional Chinese medicine composition has treatment effects on alopecia areata, alopecia in a resting period, alopecia in a growing period, scar alopecia and androgen-derived alopecia.

The invention discloses an active polypeptide for promoting healing of oral ulcer and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the active polypeptide NPTX3 capable of promoting healing of the oral ulcer is DLKPIAEDIPSLEK. An in-vitro experiment result shows that the polypeptide NPTX3 can remarkably promote the scratch closure of the human immortalized keratinocytes at the concentration as low as 500 pM. Transwell migration experiments further prove that the polypeptide NPTX3 can obviously enhance the migration ability of HaCaT cells at the concentrations of 1nM and 10nM, which prompts that the polypeptide NPTX3 may accelerate wound repair by promoting epithelial cell migration. In an SD (Sprague Dawley) rat oral ulcer model, the ulcer healing rate can be obviously improved by locally applying the polypeptide NPTX3 (1 nM, 10 nM). The polypeptide NPTX3 provided by the invention shows excellent activity of promoting cell migration and tissue repair at an extremely low dose, has the advantages of low effective dose, strong biological activity, high safety and the like, and provides an efficient and mild new choice for drug treatment of oral ulcer.

The invention belongs to the technical field of cosmetics, and particularly discloses mannosylerythritol lipid (MELs) serving as a PPAR alpha agonist and application of the MELs in cosmetics. The MELs is a single component, and can significantly activate keratinocyte PPARalpha and a downstream pathway thereof, promote synthesis of glucosylceramide and hyaluronic acid, up-regulate expression of barrier related proteins (OCLN, CLDN1, IVL, TGM1 and FLG) and aquaporin AQP3, inhibit inflammatory factors IL-1beta and TNF-alpha, and realize endogenous skin barrier repair. According to the invention, MELs is used as a PPAR alpha agonist for cosmetics for the first time, and a new raw material is provided for skin barrier repair.

A nanodiamond-reinforced nanofiber scaffold system for skin regeneration, consisting of a multilayered, electrospun nanofiber matrix formed from one or more biocompatible polymers selected from polycaprolactone (PCL), poly(lactic-co-glycolic acid) (PLGA), chitosan, gelatin or collagen, wherein nanodiamonds are present in an amount of 0.1 to 5 wt.-% are incorporated and surface-functionalized with oxygen, hydroxyl, or carboxyl groups to ensure homogeneous dispersion within the polymer matrix, the scaffold being characterized by a controlled fiber diameter in the range of 100 to 800 nm, an interconnected porosity between 60 and 90%, a tensile strength of 2 to 10 MPa, a degradation time of 2 to 8 weeks, and the ability to improve cell adhesion, proliferation, and migration of fibroblasts and keratinocytes, while simultaneously exhibiting antioxidant activity, reduced formation of reactive oxygen species, and the optional incorporation of bioactive agents selected from growth factors, antioxidants, or antimicrobial compounds to accelerate wound healing and skin tissue regeneration.

The present invention relates to a Trolox-peptide conjugate having a structure in which Trolox and a peptide are chemically bonded. The Trolox-peptide conjugate not only very effectively inhibits the activity of 5α-reductase, but also inhibits the death of papilla cells and keratinocytes, promotes the growth thereof, and has antioxidative effects, and thus can remarkably promote hair formation while avoiding or preventing hair loss.

This invention discloses a method for culturing skin organoids for large-scale production and the skin organoids used for large-scale production, belonging to the fields of tissue engineering and biomanufacturing technology. The method involves laying a dermal matrix layer composed of orthogonal double-network hydrogels embedding fibroblasts in a bioreactor containing multiple independently operable culture modules. After inoculating keratinocytes, negative pressure is used to drive a uniform descent of the culture medium level to achieve gas-liquid interface culture. The first network of the orthogonal double-network hydrogel is formed by photocrosslinking of methacrylamide recombinant collagen, and the second network is formed by Michael addition of thiolated polysaccharides and multi-arm polyethylene glycol maleimide. During the culture process, the barrier maturity is assessed in real time by online monitoring of transepithelial resistance, and the negative pressure is controlled accordingly. A single batch can produce 3000 cm³ of skin organoids. 2 The above-mentioned qualified skin organoids have a transepithelial resistance coefficient of variation of less than 10%.

The invention discloses an application of a Rap1 gene in preparation of a medicine for promoting healing of a diabetic wound, and further discloses an application of a recombinant vector, a recombinant microorganism and / or a transgenic cell line containing a nucleic acid molecule for coding the Rap1 in preparation of the medicine for promoting healing of the diabetic wound, and an application of the Rap1 in preparation of the medicine for promoting healing of the diabetic wound. The method has the advantages that the expression condition of the Rap1 in the diabetes wound tissue and the action and molecular mechanism of the Rap1 in the diabetes wound tissue are determined. Through in-vivo and in-vitro experiments, the influence of Rap1 on biological behaviors such as proliferation and adhesion of keratinocytes on the diabetic wound is researched; the molecular mechanism of the Rap1 for regulating and controlling the biological behaviors of the endothelial cells of the diabetic wound surface is deeply explored, the interaction relationship between the Rap1 and other signal channels is disclosed, and a basis is provided for developing new therapeutic drugs.

The present invention relates to a non-therapeutic cosmetic composition for increasing the cellular mitochondrial respiration of keratinocytes underlying the stratum corneum of the epidermis, comprising an active complex: extracts of Melaleuca alternifolia, extracts of Lavandula hybrida, and melatonin. The invention also relates to the use of this non-therapeutic cosmetic composition for increasing the cellular mitochondrial respiration of keratinocytes underlying the stratum corneum of the epidermis.

This invention discloses a method for inducing pluripotent stem cells to differentiate into skin keratinocytes and its culture medium, solving problems such as long differentiation cycles, low yields, insufficient purity, and animal-derived contamination in existing technologies. The first stage uses medium I containing FGF2 and tanshinone IIA to promote mesodermal differentiation. The second stage uses medium II containing BMP4, EGF, dexamethasone, and PVA to regulate and synergistically induce the BMP / ERK signaling pathway. The final stage uses medium III for expansion culture, obtaining fibroblasts with a purity >99% within 20 days. This method is non-invasive, simple, and low-cost, with potential for large-scale production. The obtained cells can be used for skin regeneration, disease modeling, drug screening, and clinical treatment, demonstrating significant medical application and industrial transformation value.

This invention belongs to the field of skin-like tissue preparation technology, and relates to a method for constructing ordered skin-like tissue with magnetic field assistance. The method involves directional cryo-casting to prepare a layered ordered hydrogel, providing skin-like seed cells, and culturing and expanding these cells in large quantities using a complete culture medium to obtain skin-like cells. The cultured skin-like cells are then co-cultured with iron oxide nanoparticles to prepare magnetized skin-like cells. These magnetized skin-like cells are then co-cultured with the layered ordered hydrogel, and magnetic fields are applied to both sides to induce the magnetized skin-like cells to enter the layered ordered hydrogel, resulting in a hydrogel scaffold. After washing the obtained hydrogel scaffold, it is transferred to a complete culture medium, and keratinocytes are seeded on the surface of the hydrogel scaffold and cultured to prepare an ordered skin-like tissue. This invention can effectively regulate the migration and arrangement of fibroblasts, providing a physical basis for the arrangement of the extracellular matrix, especially collagen.

This invention relates to the field of probiotic screening and application technology, specifically to a Bifidobacterium adolescentis HC2916 that inhibits melanin synthesis, its microbial preparations, and applications. Bifidobacterium adolescentis HC2916 was deposited on May 16, 2023, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 27352. This strain exhibits excellent antioxidant capacity, capable of scavenging various free radicals and inhibiting lipid peroxidation. Furthermore, its fermentation supernatant and lysate significantly downregulate the protein and mRNA expression of MITF, a core factor in melanin production signaling, and inhibit the expression of its downstream key enzymes TYRP1 and TYRP2. This effectively suppresses UVA-induced increases in melanin content in skin keratinocytes, demonstrating promising application prospects in the field of skin whitening.

The invention discloses a construction method of a spontaneous lupus adipositis animal model, which comprises the following steps: constructing keratinocytes with genotypes of PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-Cre < + > / -and PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-CreERT < 2 + > / -and fat cells into a conditional PPAR [gamma]-active receptor gamma gene knockout mouse, so as to construct the animal model with the spontaneous lupus adipositis animal model. Then knocking out PPAR gamma genes in keratinocytes and adipocytes by using a gene knockout activator, so that the mice spontaneously have the phenotypes of lupus septicaemia, including local skin unhairing, lipoatrophy, persistent skin lesion, proteinuria and serum autoantibodies; histological examination finds that lobular adipositis, glomerular volume increase, mesangial cell hyperplasia, inflammatory cell infiltration, glomerular IgG deposition and the like are mainly caused by dermal immune cell infiltration and subcutaneous fat layer lymphocyte infiltration, clinical symptoms of patients with lupus adipositis are simulated, and an important tool is provided for related research of lupus adipositis.

The invention belongs to the technical field of protein engineering, and discloses a humanized collagen XVII type polypeptide as well as a preparation method and application thereof. The amino acid sequence of the humanized collagen XVII type polypeptide is as shown in SEQ ID NO.1, and the polynucleotide sequence for coding the humanized collagen XVII type polypeptide is as shown in SEQ ID NO.2. The invention also provides application of the polypeptide in preparation of a protein product with functions of preventing hair loss and growing hair and / or repairing, resisting wrinkles and tightening skin. The application proves that the humanized collagen XVII type polypeptide can promote proliferation of hair papilla cells, keratinocytes and fibroblasts and promote up-regulation of expression of beta-Catenin signal channel protein closely related to hair growth in the hair papilla cells; the up-regulation expression of fibroblast type III collagen, type IV collagen, type VII collagen, fibronectin and elastin is promoted, so that the polypeptide is proved to have the effects of preventing hair loss and growing hair and / or repairing, resisting wrinkles and tightening skin.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a benzenesulfonic acid or benzenesulfonic acid derivative-guanidine eutectic crystal as well as a preparation method and application thereof. The benzenesulfonic acid or benzenesulfonic acid derivative-guanidine eutectic is a benzenesulfonic acid or benzenesulfonic acid derivative and guanidine eutectic, and the molar ratio of benzenesulfonic acid or benzenesulfonic acid derivative to guanidine is 1: (1-2). According to the invention, a proper benzenesulfonic acid derivative is screened and is taken as a ligand to be combined with guanidine, so that a series of benzenesulfonic acid or benzenesulfonic acid derivative-guanidine eutectic crystals are successfully synthesized. The eutectic can promote proliferation and migration of fibroblasts, vascular endothelial cells and keratinocytes in skin, reduce apoptosis of skin peripheral nerves and promote growth of axons so as to realize rapid healing of diabetic wounds. Meanwhile, after benzenesulfonic acid and derivatives thereof form eutectic crystals with guanidine, slow release of guanidine ions can be realized, and potential toxicity of guanidine is reduced while the drug effect is improved.